organization · Reporting owner

ABBOTT LABORATORIES

Disclosed activity across 8 companies

Tapewire entity: 2314
SEC CIK: 0000001800

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AQUABOUNTY TECHNOLOGIES INCAQB · Entity 8187	10% owner	December 30, 2016	December 30, 2016
AbbVie Inc.ABBV · Entity 2800	10% owner	December 12, 2012	December 14, 2012

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AQUABOUNTY TECHNOLOGIES INC

Report date December 30, 2016 · Filed December 30, 2016

Jointly reported with CFR International SpA

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock , par value $0.001 per shareSEC Table I · non-derivative	IndirectThrough CFR International SpA and Western Pharmaceuticals SA.	22,130,040	Reported balance Holding disclosure · report date 2016-12-30 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 22,130,040

AbbVie Inc.

Report date December 12, 2012 · Filed December 14, 2012

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stock, $0.01 par valueSEC Table I · non-derivative	Direct	0	Reported balance After 2012-12-12 transaction · row 1 1 source row Row 1 · 2012-12-12 · Other · Disposed 101 · Balance 0 F1: The record date for the distribution by Abbott Laboratories ("Abbott") of all of its shares of AbbVie Inc. ("AbbVie") to the holders of Abbott common stock was December 12, 2012 at the close of business. The distribution of the shares is scheduled to occur on January 1, 2013.

Filing footnotes · ownership attribution and instrument terms

F1: The record date for the distribution by Abbott Laboratories ("Abbott") of all of its shares of AbbVie Inc. ("AbbVie") to the holders of Abbott common stock was December 12, 2012 at the close of business. The distribution of the shares is scheduled to occur on January 1, 2013.

Past disclosures · reporting ended (6)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ABBOTT MEDICAL OPTICS INC

Report date February 26, 2009 · Filed February 28, 2009

Section 16 reporting ended · disclosed 2009-02-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy wholly owned subsidiary	103,565,445	Reported balance After 2009-02-26 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2009-02-26 · Purchase · Acquired 44,720,768 · Balance 103,565,445 F1: This Form 4 relates to shares of common stock, par value $0.01 per share (the "AMO Common Stock"), and the associated preferred stock purchase rights issued in connection with the Rights Agreement, dated June 24, 2002, by and between Advanced Medical Optics, Inc., a Delaware corporation ("AMO"), and Mellon Investor Services, LLC (together with the AMO Common Stock, the "AMO Shares"), of AMO. F2: The AMO Shares that are the subject of this report were acquired by Rainforest Acquisition Inc., a Delaware corporation and a wholly-owned subsidiary of Abbott (the "Purchaser"), upon the exercise of the "top-up" option described in the Tender Offer Statement on Schedule TO, as amended or supplemented, initially filed with the Securities and Exchange Commission on January 27, 2009 by Abbott and the Purchaser. F3: The amount of AMO Shares set forth in Column 5 of Table I reflects a downward adjustment of 1,537 AMO Shares to the number of AMO Shares previously disclosed as being subject to guaranteed delivery procedures and includes 4,469,463 AMO Shares tendered in the tender offer that remain subject to guaranteed delivery procedures.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 relates to shares of common stock, par value $0.01 per share (the "AMO Common Stock"), and the associated preferred stock purchase rights issued in connection with the Rights Agreement, dated June 24, 2002, by and between Advanced Medical Optics, Inc., a Delaware corporation ("AMO"), and Mellon Investor Services, LLC (together with the AMO Common Stock, the "AMO Shares"), of AMO.

F2: The AMO Shares that are the subject of this report were acquired by Rainforest Acquisition Inc., a Delaware corporation and a wholly-owned subsidiary of Abbott (the "Purchaser"), upon the exercise of the "top-up" option described in the Tender Offer Statement on Schedule TO, as amended or supplemented, initially filed with the Securities and Exchange Commission on January 27, 2009 by Abbott and the Purchaser.

F3: The amount of AMO Shares set forth in Column 5 of Table I reflects a downward adjustment of 1,537 AMO Shares to the number of AMO Shares previously disclosed as being subject to guaranteed delivery procedures and includes 4,469,463 AMO Shares tendered in the tender offer that remain subject to guaranteed delivery procedures.

FACET BIOTECH CORP

Report date April 20, 2010 · Filed April 21, 2010

Jointly reported with Amber Acquisition Inc.

Section 16 reporting ended · disclosed 2010-04-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	81,909,724	Reported balance After 2010-04-20 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2010-04-20 · Purchase · Acquired 62,652,055 · Balance 81,909,724 F1: This form is a joint filing by Abbott Laboratories ("Abbott") and Amber Acquisition Inc., a wholly-owned subsidiary of Abbott (the "Purchaser"). F2: This Form 4 relates to shares of common stock, par value $0.01 per share (the "Common Stock"), and the associated preferred stock purchase rights issued in connection with the Rights Agreement, dated as of September 7, 2009, as amended by the amendments thereto dated as of December 15, 2009, December 16, 2009 and March 9, 2010, by and between Facet and Mellon Investor Services LLC (together with the Common Stock, the "Shares"), of Facet. F3: Reflects Shares of Facet acquired by the Purchaser upon the exercise of the "top-up" option described in the Tender Offer Statement on Schedule TO, as amended or supplemented, initially filed with the Securities and Exchange Commission on March 23, 2010 by Abbott and the Purchaser (the "Schedule TO"). F4: Following the exercise of the "top-up" option, Facet was merged with and into the Purchaser with Facet surviving the merger as a wholly-owned subsidiary of Abbott pursuant to a "short-form merger" under Delaware law as described in the Schedule TO (the "Merger"). At the effective time of the Merger, these Shares were cancelled and ceased to exist.
Common StockSEC Table I · non-derivative	Direct	1,000	Reported balance After 2010-04-21 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2010-04-21 · Other · Acquired 5,980,034 · Balance 1,000 F5: Reflects all of the outstanding shares of Facet not tendered in the offer, which may be deemed to have been acquired by Abbott and the Purchaser pursuant to the consummation of the Merger. At the effective time of the Merger, these Shares were cancelled and ceased to exist. F6: Prior to the Merger, Abbott held 1,000 shares of the common stock, no par value per share, of the Purchaser (the "Purchaser Shares"), which represented all of the issued and outstanding capital stock of the Purchaser. At the effective time of the Merger, each Purchaser Share was converted into one share of common stock of Facet, as the surviving corporation of the Merger, and as a result Abbott acquired 100% of the equity interest of Facet.

Filing footnotes · ownership attribution and instrument terms

F1: This form is a joint filing by Abbott Laboratories ("Abbott") and Amber Acquisition Inc., a wholly-owned subsidiary of Abbott (the "Purchaser").

F2: This Form 4 relates to shares of common stock, par value $0.01 per share (the "Common Stock"), and the associated preferred stock purchase rights issued in connection with the Rights Agreement, dated as of September 7, 2009, as amended by the amendments thereto dated as of December 15, 2009, December 16, 2009 and March 9, 2010, by and between Facet and Mellon Investor Services LLC (together with the Common Stock, the "Shares"), of Facet.

F3: Reflects Shares of Facet acquired by the Purchaser upon the exercise of the "top-up" option described in the Tender Offer Statement on Schedule TO, as amended or supplemented, initially filed with the Securities and Exchange Commission on March 23, 2010 by Abbott and the Purchaser (the "Schedule TO").

F4: Following the exercise of the "top-up" option, Facet was merged with and into the Purchaser with Facet surviving the merger as a wholly-owned subsidiary of Abbott pursuant to a "short-form merger" under Delaware law as described in the Schedule TO (the "Merger"). At the effective time of the Merger, these Shares were cancelled and ceased to exist.

F5: Reflects all of the outstanding shares of Facet not tendered in the offer, which may be deemed to have been acquired by Abbott and the Purchaser pursuant to the consummation of the Merger. At the effective time of the Merger, these Shares were cancelled and ceased to exist.

F6: Prior to the Merger, Abbott held 1,000 shares of the common stock, no par value per share, of the Purchaser (the "Purchaser Shares"), which represented all of the issued and outstanding capital stock of the Purchaser. At the effective time of the Merger, each Purchaser Share was converted into one share of common stock of Facet, as the surviving corporation of the Merger, and as a result Abbott acquired 100% of the equity interest of Facet.

HOSPIRA INC

Report date April 30, 2004 · Filed May 04, 2004

Section 16 reporting ended · disclosed 2004-05-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2004-04-30 transaction · row 1 1 source row Row 1 · 2004-04-30 · Other · Disposed 100 · Balance 0 F1: The shares of Common Stock were distributed to holders of Abbott Laboratories common shares in connection with the spin-off of Hospira, Inc. from Abbott Laboratories on April 30, 2004, and were not part of a sale of any kind.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Common Stock were distributed to holders of Abbott Laboratories common shares in connection with the spin-off of Hospira, Inc. from Abbott Laboratories on April 30, 2004, and were not part of a sale of any kind.

ICAGEN INC

Report date February 08, 2005 · Filed February 10, 2005

Section 16 reporting ended · disclosed 2005-02-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,646,535	Ending reported balance After 2005-02-08 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2005-02-08 · Conversion · Acquired 1,191,300 · Balance 1,191,300 F1: Upon the closing of the Issuer's public offering, the Series E Convertible Preferred Stock converted on a 1-for-1 basis into Common Stock. Row 2 · 2005-02-08 · Conversion · Acquired 455,235 · Balance 1,646,535 F2: Upon the closing of the Issuer's public offering, the Series E-1 Convertible Preferred Stock converted on a 1.138-for-1 basis into Common Stock.
Series E Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2005-02-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2005-02-08 · Conversion · Disposed 1,191,300 · Balance 0 F1: Upon the closing of the Issuer's public offering, the Series E Convertible Preferred Stock converted on a 1-for-1 basis into Common Stock. F3: These shares were immediately exercisable. They had no expiration date.
Series E-1 Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2005-02-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2005-02-08 · Conversion · Disposed 400,000 · Balance 0 F2: Upon the closing of the Issuer's public offering, the Series E-1 Convertible Preferred Stock converted on a 1.138-for-1 basis into Common Stock. F3: These shares were immediately exercisable. They had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Upon the closing of the Issuer's public offering, the Series E Convertible Preferred Stock converted on a 1-for-1 basis into Common Stock.

F2: Upon the closing of the Issuer's public offering, the Series E-1 Convertible Preferred Stock converted on a 1.138-for-1 basis into Common Stock.

F3: These shares were immediately exercisable. They had no expiration date.

Mylan II B.V.

Report date March 23, 2017 · Filed March 24, 2017

Jointly reported with Abbott Products, Abbott Investments Luxembourg S.A R.L.

Section 16 reporting ended · disclosed 2017-03-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares, nominal value Euro 0.01 per shareSEC Table I · non-derivative	IndirectBy Subsidiaries	25,750,000	Reported balance After 2017-03-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-03-23 · Sale · Disposed 44,000,000 · Balance 25,750,000

Trubion Pharmaceuticals, Inc

Report date October 28, 2010 · Filed December 10, 2010

Section 16 reporting ended · disclosed 2010-12-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2010-10-28 transaction · row 1 1 source row Row 1 · 2010-10-28 · Other · Disposed 2,243,649 · Balance 0 F1: This Form 4 relates to shares of common stock, par value $0.001 of Trubion Pharmaceuticals, Inc. ("Trubion Common Stock"). On October 28, 2010, pursuant to an Agreement and Plan of Merger dated August 12, 2010, as amended, by and among Emergent BioSolutions Inc. ("Emergent"), 35406 LLC, a direct wholly-owned subsidiary of Emergent, 30333 Inc., an indirect wholly-owned subsidiary of Emergent and Trubion Pharmaceuticals, Inc. ("Trubion"), Emergent completed its acquisition of Trubion (the "Merger"). (Continued in Footnote 2) F2: (Continued from Footnote 1) As a result of the Merger each of the 2,243,649 shares of Trubion Common Stock owned by Abbott Laboratories outstanding immediately prior to the effective time of the Merger was canceled and converted into the right to receive: an amount in cash equal to $1.365; 0.1641 of a share of common stock of Emergent; and one Contingent Value Right, which entitles the holder thereof to receive a pro rata portion of certain contingent payments following the achievement of future development milestones under certain of Trubion's collaboration agreements.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 relates to shares of common stock, par value $0.001 of Trubion Pharmaceuticals, Inc. ("Trubion Common Stock"). On October 28, 2010, pursuant to an Agreement and Plan of Merger dated August 12, 2010, as amended, by and among Emergent BioSolutions Inc. ("Emergent"), 35406 LLC, a direct wholly-owned subsidiary of Emergent, 30333 Inc., an indirect wholly-owned subsidiary of Emergent and Trubion Pharmaceuticals, Inc. ("Trubion"), Emergent completed its acquisition of Trubion (the "Merger"). (Continued in Footnote 2)

F2: (Continued from Footnote 1) As a result of the Merger each of the 2,243,649 shares of Trubion Common Stock owned by Abbott Laboratories outstanding immediately prior to the effective time of the Merger was canceled and converted into the right to receive: an amount in cash equal to $1.365; 0.1641 of a share of common stock of Emergent; and one Contingent Value Right, which entitles the holder thereof to receive a pro rata portion of certain contingent payments following the achievement of future development milestones under certain of Trubion's collaboration agreements.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 23, 2017 Filed Mar 24, 2017 11:34 UTC	Mylan II B.V. MYL · Entity 16217	SaleOrdinary Shares, nominal value Euro 0.01 per share	44,000,000	$41.60	$1,830,400,000.00	Disclosure SEC source: 0001104659-17-019006 · a4.xml · nonDerivative · entry 1 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner Abbott Products · CIK 0001650190 · 10% owner Abbott Investments Luxembourg S.A R.L. · CIK 0001635614 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Subsidiaries Disclosed balance after: 25,750,000 Read SEC document
April 07, 2015 Filed Apr 9, 2015 20:44 UTC	Mylan II B.V. MYL · Entity 16217	OtherCall Option (Obligation to Sell) · Derivative	1	$0.00 Strike: $56.89	$0.00	Disclosure SEC source: 0001104659-15-026765 · a4.xml · derivative · entry 2 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner Abbott Established Products Holdings Gibraltar Ltd · CIK 0001635611 · 10% owner Abbott Investments Luxembourg S.A R.L. · CIK 0001635614 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Subsidiaries Disclosed balance after: 0 Underlying: Ordinary Shares · 5,250,000 shares Expires 2015-04-30 Read SEC document
April 07, 2015 Filed Apr 9, 2015 20:44 UTC	Mylan II B.V. MYL · Entity 16217	OtherOrdinary Shares, nominal value Euro 0.01 per share	5,250,000	$56.89	$298,678,800.00	Disclosure SEC source: 0001104659-15-026765 · a4.xml · nonDerivative · entry 1 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner Abbott Established Products Holdings Gibraltar Ltd · CIK 0001635611 · 10% owner Abbott Investments Luxembourg S.A R.L. · CIK 0001635614 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Subsidiaries Disclosed balance after: 69,750,000 Read SEC document
March 31, 2015 Filed Apr 2, 2015 20:34 UTC	Mylan II B.V. MYL · Entity 16217	OtherCall Option (Obligation to Sell) · Derivative	1	$0.00 Strike: $56.89	$0.00	Disclosure SEC source: 0001104659-15-025547 · a4.xml · derivative · entry 2 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner Laboratoires Fournier S.A.S. · CIK 0001635767 · 10% owner Abbott Established Products Holdings Gibraltar Ltd · CIK 0001635611 · 10% owner Abbott Investments Luxembourg S.A R.L. · CIK 0001635614 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Subsidiaries Disclosed balance after: 1 Underlying: Ordinary Shares · 5,250,000 shares Expires 2015-04-30 Read SEC document
March 31, 2015 Filed Apr 2, 2015 20:34 UTC	Mylan II B.V. MYL · Entity 16217	OtherOrdinary Shares, nominal value euro 0.01 per share	35,000,000	$56.89	$1,991,192,000.00	Disclosure SEC source: 0001104659-15-025547 · a4.xml · nonDerivative · entry 1 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner Laboratoires Fournier S.A.S. · CIK 0001635767 · 10% owner Abbott Established Products Holdings Gibraltar Ltd · CIK 0001635611 · 10% owner Abbott Investments Luxembourg S.A R.L. · CIK 0001635614 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Subsidiaries Disclosed balance after: 75,000,000 Read SEC document
December 12, 2012 Filed Dec 14, 2012 22:22 UTC	AbbVie Inc. ABBV · Entity 2800	OtherCommon stock, $0.01 par value	101	$0.00	$0.00	Disclosure SEC source: 0001179110-12-017658 · edgar.xml · nonDerivative · entry 1 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The record date for the distribution by Abbott Laboratories ("Abbott") of all of its shares of AbbVie Inc. ("AbbVie") to the holders of Abbott common stock was December 12, 2012 at the close of business. The distribution of the shares is scheduled to occur on January 1, 2013. Read SEC document
October 28, 2010 Filed Dec 10, 2010 21:54 UTC	Trubion Pharmaceuticals, Inc TRBN · Entity 16931	OtherCommon Stock	2,243,649	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-10-062171 · a4.xml · nonDerivative · entry 1 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 relates to shares of common stock, par value $0.001 of Trubion Pharmaceuticals, Inc. ("Trubion Common Stock"). On October 28, 2010, pursuant to an Agreement and Plan of Merger dated August 12, 2010, as amended, by and among Emergent BioSolutions Inc. ("Emergent"), 35406 LLC, a direct wholly-owned subsidiary of Emergent, 30333 Inc., an indirect wholly-owned subsidiary of Emergent and Trubion Pharmaceuticals, Inc. ("Trubion"), Emergent completed its acquisition of Trubion (the "Merger"). (Continued in Footnote 2) F2 · kind: (Continued from Footnote 1) As a result of the Merger each of the 2,243,649 shares of Trubion Common Stock owned by Abbott Laboratories outstanding immediately prior to the effective time of the Merger was canceled and converted into the right to receive: an amount in cash equal to $1.365; 0.1641 of a share of common stock of Emergent; and one Contingent Value Right, which entitles the holder thereof to receive a pro rata portion of certain contingent payments following the achievement of future development milestones under certain of Trubion's collaboration agreements. F1 · shares: This Form 4 relates to shares of common stock, par value $0.001 of Trubion Pharmaceuticals, Inc. ("Trubion Common Stock"). On October 28, 2010, pursuant to an Agreement and Plan of Merger dated August 12, 2010, as amended, by and among Emergent BioSolutions Inc. ("Emergent"), 35406 LLC, a direct wholly-owned subsidiary of Emergent, 30333 Inc., an indirect wholly-owned subsidiary of Emergent and Trubion Pharmaceuticals, Inc. ("Trubion"), Emergent completed its acquisition of Trubion (the "Merger"). (Continued in Footnote 2) F2 · shares: (Continued from Footnote 1) As a result of the Merger each of the 2,243,649 shares of Trubion Common Stock owned by Abbott Laboratories outstanding immediately prior to the effective time of the Merger was canceled and converted into the right to receive: an amount in cash equal to $1.365; 0.1641 of a share of common stock of Emergent; and one Contingent Value Right, which entitles the holder thereof to receive a pro rata portion of certain contingent payments following the achievement of future development milestones under certain of Trubion's collaboration agreements. F1 · price: This Form 4 relates to shares of common stock, par value $0.001 of Trubion Pharmaceuticals, Inc. ("Trubion Common Stock"). On October 28, 2010, pursuant to an Agreement and Plan of Merger dated August 12, 2010, as amended, by and among Emergent BioSolutions Inc. ("Emergent"), 35406 LLC, a direct wholly-owned subsidiary of Emergent, 30333 Inc., an indirect wholly-owned subsidiary of Emergent and Trubion Pharmaceuticals, Inc. ("Trubion"), Emergent completed its acquisition of Trubion (the "Merger"). (Continued in Footnote 2) F2 · price: (Continued from Footnote 1) As a result of the Merger each of the 2,243,649 shares of Trubion Common Stock owned by Abbott Laboratories outstanding immediately prior to the effective time of the Merger was canceled and converted into the right to receive: an amount in cash equal to $1.365; 0.1641 of a share of common stock of Emergent; and one Contingent Value Right, which entitles the holder thereof to receive a pro rata portion of certain contingent payments following the achievement of future development milestones under certain of Trubion's collaboration agreements. Read SEC document
April 21, 2010 Filed Apr 21, 2010 21:07 UTC	FACET BIOTECH CORP FACT · Entity 16988	OtherCommon Stock	5,980,034	$27.00	$161,460,918.00	Disclosure SEC source: 0001104659-10-021021 · a4.xml · nonDerivative · entry 2 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner Amber Acquisition Inc. · CIK 0001486751 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F5 · shares: Reflects all of the outstanding shares of Facet not tendered in the offer, which may be deemed to have been acquired by Abbott and the Purchaser pursuant to the consummation of the Merger. At the effective time of the Merger, these Shares were cancelled and ceased to exist. F6 · balance_after: Prior to the Merger, Abbott held 1,000 shares of the common stock, no par value per share, of the Purchaser (the "Purchaser Shares"), which represented all of the issued and outstanding capital stock of the Purchaser. At the effective time of the Merger, each Purchaser Share was converted into one share of common stock of Facet, as the surviving corporation of the Merger, and as a result Abbott acquired 100% of the equity interest of Facet. Read SEC document
April 20, 2010 Filed Apr 21, 2010 21:07 UTC	FACET BIOTECH CORP FACT · Entity 16988	PurchaseCommon Stock	62,652,055	$27.00	$1,691,605,485.00	Disclosure SEC source: 0001104659-10-021021 · a4.xml · nonDerivative · entry 1 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner Amber Acquisition Inc. · CIK 0001486751 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,909,724 F1 · security: This form is a joint filing by Abbott Laboratories ("Abbott") and Amber Acquisition Inc., a wholly-owned subsidiary of Abbott (the "Purchaser"). F2 · security: This Form 4 relates to shares of common stock, par value $0.01 per share (the "Common Stock"), and the associated preferred stock purchase rights issued in connection with the Rights Agreement, dated as of September 7, 2009, as amended by the amendments thereto dated as of December 15, 2009, December 16, 2009 and March 9, 2010, by and between Facet and Mellon Investor Services LLC (together with the Common Stock, the "Shares"), of Facet. F3 · shares: Reflects Shares of Facet acquired by the Purchaser upon the exercise of the "top-up" option described in the Tender Offer Statement on Schedule TO, as amended or supplemented, initially filed with the Securities and Exchange Commission on March 23, 2010 by Abbott and the Purchaser (the "Schedule TO"). F4 · balance_after: Following the exercise of the "top-up" option, Facet was merged with and into the Purchaser with Facet surviving the merger as a wholly-owned subsidiary of Abbott pursuant to a "short-form merger" under Delaware law as described in the Schedule TO (the "Merger"). At the effective time of the Merger, these Shares were cancelled and ceased to exist. Read SEC document
February 26, 2009 Filed Feb 28, 2009 01:36 UTC	ABBOTT MEDICAL OPTICS INC EYE · Entity 17075	PurchaseCommon Stock	44,720,768	$22.00	$983,856,896.00	Disclosure SEC source: 0001104659-09-013218 · a4.xml · nonDerivative · entry 1 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By wholly owned subsidiary Disclosed balance after: 103,565,445 F1 · security: This Form 4 relates to shares of common stock, par value $0.01 per share (the "AMO Common Stock"), and the associated preferred stock purchase rights issued in connection with the Rights Agreement, dated June 24, 2002, by and between Advanced Medical Optics, Inc., a Delaware corporation ("AMO"), and Mellon Investor Services, LLC (together with the AMO Common Stock, the "AMO Shares"), of AMO. F2 · security: The AMO Shares that are the subject of this report were acquired by Rainforest Acquisition Inc., a Delaware corporation and a wholly-owned subsidiary of Abbott (the "Purchaser"), upon the exercise of the "top-up" option described in the Tender Offer Statement on Schedule TO, as amended or supplemented, initially filed with the Securities and Exchange Commission on January 27, 2009 by Abbott and the Purchaser. F3 · security: The amount of AMO Shares set forth in Column 5 of Table I reflects a downward adjustment of 1,537 AMO Shares to the number of AMO Shares previously disclosed as being subject to guaranteed delivery procedures and includes 4,469,463 AMO Shares tendered in the tender offer that remain subject to guaranteed delivery procedures. Read SEC document
February 25, 2009 Filed Feb 25, 2009 21:28 UTC	ABBOTT MEDICAL OPTICS INC EYE · Entity 17075	PurchaseCommon Stock	56,395,914	$22.00	$1,240,710,108.00	Disclosure SEC source: 0001104659-09-012102 · a4.xml · nonDerivative · entry 1 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner Rainforest Acquisition Inc. · CIK 0001454341 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By wholly owned subsidiary Disclosed balance after: 58,846,214 F1 · security: This form is a joint filing by Abbott Laboratories ("Abbott") and Rainforest Acquisition Inc., a wholly-owned subsidiary of Abbott (the "Purchaser"). This Form 4 relates to shares of common stock, par value $0.01 per share (the "AMO Common Stock"), and the associated preferred stock purchase rights issued in connection with the Rights Agreement, dated June 24, 2002, by and between Advanced Medical Optics, Inc., a Delaware corporation ("AMO"), and Mellon Investor Services, LLC (together with the AMO Common Stock, the "AMO Shares"), of AMO. F2 · security: The AMO Shares that are the subject of this report were acquired by the Purchaser upon the expiration of the Purchaser's offer to purchase all of the outstanding AMO Shares as disclosed in the Tender Offer Statement on Schedule TO, as amended or supplemented, initially filed with the Securities and Exchange Commission on January 27, 2009 by Abbott and the Purchaser. F3 · security: Includes 6,657,258 AMO Shares tendered through guaranteed delivery procedures. Read SEC document
February 08, 2005 Filed Feb 10, 2005 18:57 UTC	ICAGEN INC ICGN · Entity 13934	ConversionSeries E-1 Convertible Preferred Stock · Derivative	400,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001181431-05-008571 · rrd66556.xml · derivative · entry 4 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 455,235 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Upon the closing of the Issuer's public offering, the Series E-1 Convertible Preferred Stock converted on a 1.138-for-1 basis into Common Stock. F2 · price: Upon the closing of the Issuer's public offering, the Series E-1 Convertible Preferred Stock converted on a 1.138-for-1 basis into Common Stock. F3 · derivative.exercise_date: These shares were immediately exercisable. They had no expiration date. F3 · derivative.expiration_date: These shares were immediately exercisable. They had no expiration date. Read SEC document
February 08, 2005 Filed Feb 10, 2005 18:57 UTC	ICAGEN INC ICGN · Entity 13934	ConversionSeries E Convertible Preferred Stock · Derivative	1,191,300	Not disclosed	Not disclosed	Disclosure SEC source: 0001181431-05-008571 · rrd66556.xml · derivative · entry 3 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,191,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's public offering, the Series E Convertible Preferred Stock converted on a 1-for-1 basis into Common Stock. F1 · price: Upon the closing of the Issuer's public offering, the Series E Convertible Preferred Stock converted on a 1-for-1 basis into Common Stock. F3 · derivative.exercise_date: These shares were immediately exercisable. They had no expiration date. F3 · derivative.expiration_date: These shares were immediately exercisable. They had no expiration date. Read SEC document
February 08, 2005 Filed Feb 10, 2005 18:57 UTC	ICAGEN INC ICGN · Entity 13934	ConversionCommon Stock	455,235	Not disclosed	Not disclosed	Disclosure SEC source: 0001181431-05-008571 · rrd66556.xml · nonDerivative · entry 2 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,646,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Upon the closing of the Issuer's public offering, the Series E-1 Convertible Preferred Stock converted on a 1.138-for-1 basis into Common Stock. Read SEC document
February 08, 2005 Filed Feb 10, 2005 18:57 UTC	ICAGEN INC ICGN · Entity 13934	ConversionCommon Stock	1,191,300	Not disclosed	Not disclosed	Disclosure SEC source: 0001181431-05-008571 · rrd66556.xml · nonDerivative · entry 1 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's public offering, the Series E Convertible Preferred Stock converted on a 1-for-1 basis into Common Stock. Read SEC document
April 30, 2004 Filed May 4, 2004 20:38 UTC	HOSPIRA INC HSP · Entity 17647	OtherCommon Stock	100	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-04-009555 · edgar.xml · nonDerivative · entry 1 ABBOTT LABORATORIES · CIK 0000001800 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The shares of Common Stock were distributed to holders of Abbott Laboratories common shares in connection with the spin-off of Hospira, Inc. from Abbott Laboratories on April 30, 2004, and were not part of a sale of any kind. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.